Skip to main content
Insights
/ Webinars

Next Level Partnering with Novartis

Novartis
Next Level Partnering with Novartis

Access webinar replay

Business email
First name
Last name
Company name
Job title
Which sector best reflects your role?
By submitting this form, you agree to receive email communications from Inpart as well as the storing and processing of your personal data by Inpart as detailed in the Privacy Statement. You may unsubscribe from these communications at any time.

In 2024, Novartis led the pharma industry for in-licensing and partnering, signing 30 major early-stage deals. At the core of Novartis’ dealmaking is Ronny Gal, Chief Strategy & Growth Officer, a seasoned pharma leader with a reputation for driving innovation and closing big deals, who will be joining us for an exclusive webinar ahead of BIO 2025.

Panelists

Ronny Gal
Ronny Gal
Chief Strategy & Growth Officer, Novartis

On the webinar, Ronny will review Novartis’ pipeline and external innovation strategies, sharing stories behind some of the deals they’ve recently closed, and explaining how biotechs and research institutes can maximize their impact at BIO and other partnering conferences.

Watch the replay to learn:

  • Novartis’ target TAs and what’s needed to fill their pipeline
  • What goes into closing multiple $1-billion deals in a year
  • Practical steps to maximize partnering outcomes at BIO 2025

About Novartis

Novartis is a global biopharmaceutical company working to reimagine medicine that improves and extends lives so that patients, healthcare professionals, and society are empowered in the face of serious disease. Medicines developed by Novartis reach more than 250 million people worldwide.